{"The": [0, 146, 175], "acronym": [1], "ESKAPE": [2, 82, 160], "includes": [3], "six": [4], "nosocomial": [5], "pathogens": [6, 83, 137], "that": [7], "exhibit": [8], "multidrug": [9, 35], "resistance": [10], "and": [11, 23, 38, 56, 106, 131, 164, 170], "virulence:": [12], "Enterococcus": [13], "faecium,": [14], "Staphylococcus": [15], "aureus,": [16], "Klebsiella": [17], "pneumoniae,": [18], "Acinetobacter": [19], "baumannii,": [20], "Pseudomonas": [21], "aeruginosa": [22], "Enterobacter": [24], "spp.": [25], "Persistent": [26], "use": [27, 94], "of": [28, 34, 70, 87, 95, 133, 148, 181, 225], "antibiotics": [29, 96], "has": [30], "provoked": [31], "the": [32, 47, 85, 88, 124, 154, 179, 223], "emergence": [33], "resistant": [36, 41, 76], "(MDR)": [37], "extensively": [39], "drug": [40, 75], "(XDR)": [42], "bacteria,": [43], "which": [44, 204], "render": [45], "even": [46], "most": [48], "effective": [49], "drugs": [50], "ineffective.": [51], "Extended": [52], "spectrum": [53], "\u03b2-lactamase": [54], "(ESBL)": [55], "carbapenemase": [57], "producing": [58], "Gram": [59], "negative": [60], "bacteria": [61], "have": [62, 141], "emerged": [63], "as": [64, 93], "an": [65, 218], "important": [66], "therapeutic": [67], "challenge.": [68], "Development": [69], "novel": [71], "therapeutics": [72], "to": [73, 123, 152, 158, 196], "treat": [74, 159], "infections,": [77, 161], "especially": [78], "those": [79], "caused": [80], "by": [81], "is": [84, 151], "need": [86], "hour.": [89], "Alternative": [90], "therapies": [91, 120, 156, 189], "such": [92], "in": [97, 168, 172, 192, 194], "combination": [98, 193], "or": [99, 187, 221], "with": [100, 121], "adjuvants,": [101], "bacteriophages,": [102], "antimicrobial": [103], "peptides,": [104], "nanoparticles": [105], "photodynamic": [107], "light": [108], "therapy": [109], "are": [110, 190, 205], "widely": [111], "reported.": [112], "Many": [113], "reviews": [114], "published": [115], "till": [116], "date": [117], "describe": [118, 153], "these": [119], "respect": [122], "various": [125], "agents": [126], "used,": [127], "their": [128, 162, 198], "dosage": [129], "details": [130], "mechanism": [132], "action": [134], "against": [135], "MDR": [136], "but": [138], "very": [139], "few": [140], "focused": [142], "specifically": [143], "on": [144, 203], "ESKAPE.": [145], "objective": [147], "this": [149], "review": [150, 176], "alternative": [155], "reported": [157], "advantages": [163], "limitations,": [165, 200], "potential": [166], "application": [167], "vivo": [169], "status": [171], "clinical": [173, 211], "trials.": [174], "further": [177], "highlights": [178], "importance": [180], "a": [182], "combinatorial": [183], "approach,": [184], "wherein": [185], "two": [186], "more": [188], "used": [191], "order": [195], "overcome": [197], "individual": [199], "additional": [201], "studies": [202], "warranted,": [206], "before": [207], "translating": [208], "them": [209], "into": [210], "practice.": [212], "These": [213], "advances": [214], "could": [215], "possibly": [216], "give": [217], "alternate": [219], "solution": [220], "extend": [222], "lifetime": [224], "current": [226], "antimicrobials.": [227]}